Skip to content
New issue

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.

Already on GitHub? Sign in to your account

Error at parsing Abstract - PMID 35517058 #26

Open
EhsanBitaraf opened this issue Jun 25, 2023 · 0 comments
Open

Error at parsing Abstract - PMID 35517058 #26

EhsanBitaraf opened this issue Jun 25, 2023 · 0 comments
Labels
bug Something isn't working

Comments

@EhsanBitaraf
Copy link
Owner

Describe the bug
triplea\service\repository\state\parsing_details.py
line 190, in parsing_details
article.Abstract = pubmed_article_data["Abstract"]["AbstractText"][

To Reproduce
Steps to reproduce the behavior:
Parse article 35517058

Screenshots

"Abstract" : {
    "AbstractText" : {
        "sup" : [
            "Patients with heavily pretreated, late-stage cancer and bone metastasis are usually poor candidates for further chemotherapy. Previously, we showed that association to lipid nanoparticles (LDE) drastically decreases the toxicity of anti-cancer drugs. Here, we tested the hypothesis that paclitaxel (PTX) carried in LDE could benefit end-of-life patients with painful bone metastases that had been previously treated with conventional PTX. Methods: Eighteen consecutive patients with late-stage cancer, 8 with breast, 5 with prostate and 5 with lung carcinoma, aged 59±9 years, were included in this study. All were receiving opioid medication. LDE-PTX was administered at 175 mg/m 2 every 3 weeks until disease progression. Clinical imaging examinations and serum biochemistry determinations were performed to monitor disease progression. Intensity of bone pain, use of opioid medications and occurrence of pathological bone fractures were also evaluated. Results: In total, 104 chemotherapy cycles were performed and none of the patients showed clinical and laboratorial toxicities or pathological bone fractures. In all patients, pain was reduced so as to allow substitution of non-opioid for opioid medication. Median progression-free survival (PFS) was four months (95% CI 2.4-5.5), but in five patients PFS was longer than 6 months. Conclusions: Absence of observable clinical and laboratorial toxicities from LDE-PTX treatment, improvement of bone pain and the possible effect on PFS in some patients, despite previous use of conventional PTX, suggest that LDEPTX merits further clinical investigation", 
            "."
        ]
    }, 
    "CopyrightInformation" : "© 2022 The Authors."
}

Desktop (please complete the following information):

  • OS: windows
  • Browser [e.g. chrome, safari]
  • Version 0.0.2
@EhsanBitaraf EhsanBitaraf added the bug Something isn't working label Jun 25, 2023
Sign up for free to join this conversation on GitHub. Already have an account? Sign in to comment
Labels
bug Something isn't working
Projects
None yet
Development

No branches or pull requests

1 participant